idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Grafik: idw-Logo

idw - Informationsdienst
Wissenschaft

Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
21.03.2021 14:30

Researchers from Greifswald Germany report breakthrough in SARS-CoV2 vaccination related thrombotic complications

Constanze Steinke Pressearbeit
Universität Greifswald

    Vaccines are important for managing the COVID-19 pandemic caused by SARS-CoV-2. However, following widespread vaccination using a recombinant adenoviral vector encoding the spike protein antigen of SARS-CoV-2 (AZD1222, AstraZeneca), reports have emerged of some vaccine recipients developing unusual thrombotic events and thrombocytopenia. We investigated whether such patients could have a prothrombotic disorder caused by platelet-activating antibodies directed against a platelet protein, as a similar mechanism is known to be caused by heparin and sometimes other environmental triggers.

    Under the lead of the group of Dr Andreas Greinacher, transfusion medicine Universitätsmedizin Greifswald, Germany, researchers from the University Hospital Vienna, Austria; McMaster University Canada; the Paul Ehrlich Institut, Langen, Germany and the Greifswald Universitaetsmedizin, Greifswald Germany investigated the clinical and laboratory features of patients in Germany and Austria who developed cerebral vein thrombosis and thrombocytopenia following AZD1222 vaccination. They Transfusion Medicine team also developed a new specific confirmatory assay which allows detection of these antibodies.

    Patients tested strongly positive for anti-platelet antibodies by immunoassay; and strongly positive in the newly developed functional test (platelet activation assay) in the presence of a newly identified cofactor (still under embargo). The test allows clear differentiation between the new syndrome and the long know adverse drug effect heparin induced thrombocytopenia, (HIT). Platelet activation by the AZD1222 vaccination associated antibodies was inhibited by intravenous immunoglobulin, a widely available, approved medication.

    The Greifswald team highlights the unique collaboration of international scientists, physicians, the Paul Ehrlich Institute (German regulatory agency), treating physicians who referred blood samples and patients who agreed to donate their blood for research
    Within a short period of time, from receiving the first patient sample Tuesday, March 16, 2021 at noon until Friday, March 19 the team:

    - Identified the mechanism of SARS CoV2 vaccination induced severe thrombotic complications,
    - identified a widely available screening test, which is widely available (already confirmed by researchers in the UK),
    - develop a confirmatory test which seems to be highly sensitive and specific (cautionary note: the number of samples investigated is still limited),
    - and to identify a treatment which has the potential to rapidly deescalate the catastrophic prothrombotic mechanism. As the researcher team has shown before that IVIG is very effective in treatment of catastrophic HIT, and as HIT has a very close clinical and laboratory resemblance characteristics to these vaccine associated complications, it is highly likely that IVIG will also be an important therapeutic options (in addition to anticoagulant treatment) for these patients. IVIG is approved and available in most hospitals.

    We propose to call this syndrome VIPIT Virus/Vaccine Induced Prothrombotic Immune Thrombocytopenia.

    Universitätsmedizin Greifswald
    Christian Arns
    Leiter der Stabsstelle Kommunikation und Marketing
    Universitätsmedizin Greifswald
    Walther-Rathenau-Straße 46 * 17475 Greifswald
    Tel: +49 3834 86-52 88
    christian.arns@med.uni-greifswald.de
    http://www.medizin.uni-greifswald.de
    http://www.facebook.com/UnimedizinGreifswald
    Instagram/Twitter @UMGreifswald


    Wissenschaftliche Ansprechpartner:

    Prof. Andreas Greinacher


    Bilder

    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler
    Biologie, Medizin
    überregional
    Forschungsergebnisse
    Englisch


     

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).